PL398077A1 - Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego - Google Patents

Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego

Info

Publication number
PL398077A1
PL398077A1 PL398077A PL39807712A PL398077A1 PL 398077 A1 PL398077 A1 PL 398077A1 PL 398077 A PL398077 A PL 398077A PL 39807712 A PL39807712 A PL 39807712A PL 398077 A1 PL398077 A1 PL 398077A1
Authority
PL
Poland
Prior art keywords
composition
drug
manufacturing
treatment
multiple sclerosis
Prior art date
Application number
PL398077A
Other languages
English (en)
Inventor
Krzysztof Selmaj
Marian Szczepanik
Original Assignee
Krzysztof Selmaj
Marian Szczepanik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krzysztof Selmaj, Marian Szczepanik filed Critical Krzysztof Selmaj
Priority to PL398077A priority Critical patent/PL398077A1/pl
Publication of PL398077A1 publication Critical patent/PL398077A1/pl
Priority to ES13710308.1T priority patent/ES2684725T3/es
Priority to PCT/EP2013/052615 priority patent/WO2013117742A2/en
Priority to HUE13710308A priority patent/HUE039044T2/hu
Priority to SI201331085T priority patent/SI2812351T1/sl
Priority to DK13710308.1T priority patent/DK2812351T3/en
Priority to PT137103081T priority patent/PT2812351T/pt
Priority to US14/377,903 priority patent/US20150080313A1/en
Priority to EP13710308.1A priority patent/EP2812351B1/en
Priority to PL13710308T priority patent/PL2812351T3/pl
Priority to US16/053,217 priority patent/US20190201484A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Rehabilitation Therapy (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL398077A 2012-02-10 2012-02-10 Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego PL398077A1 (pl)

Priority Applications (11)

Application Number Priority Date Filing Date Title
PL398077A PL398077A1 (pl) 2012-02-10 2012-02-10 Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego
PL13710308T PL2812351T3 (pl) 2012-02-10 2013-02-08 Kompozycja farmaceutyczna do leczenia stwardnienia rozsianego
SI201331085T SI2812351T1 (sl) 2012-02-10 2013-02-08 Farmacevtski sestavek za zdravljenje multiple skleroze
PCT/EP2013/052615 WO2013117742A2 (en) 2012-02-10 2013-02-08 Pharmaceutical composition for the treatment of multiple sclerosis
HUE13710308A HUE039044T2 (hu) 2012-02-10 2013-02-08 Gyógyászati kompozíció sclerosis multiplex kezelésére
ES13710308.1T ES2684725T3 (es) 2012-02-10 2013-02-08 Composiciones farmacéuticas para el tratamiento de la esclerosis múltiple
DK13710308.1T DK2812351T3 (en) 2012-02-10 2013-02-08 Pharmaceutical composition for the treatment of multiple sclerosis
PT137103081T PT2812351T (pt) 2012-02-10 2013-02-08 Composição farmacêutica para o tratamento de esclerose múltipla
US14/377,903 US20150080313A1 (en) 2012-02-10 2013-02-08 Pharmaceutical composition for the treatment of multiple sclerosis
EP13710308.1A EP2812351B1 (en) 2012-02-10 2013-02-08 Pharmaceutical composition for the treatment of multiple sclerosis
US16/053,217 US20190201484A1 (en) 2012-02-10 2018-08-02 Pharmaceutical composition for the treatment of multiple sclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL398077A PL398077A1 (pl) 2012-02-10 2012-02-10 Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego

Publications (1)

Publication Number Publication Date
PL398077A1 true PL398077A1 (pl) 2012-08-27

Family

ID=46762685

Family Applications (2)

Application Number Title Priority Date Filing Date
PL398077A PL398077A1 (pl) 2012-02-10 2012-02-10 Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego
PL13710308T PL2812351T3 (pl) 2012-02-10 2013-02-08 Kompozycja farmaceutyczna do leczenia stwardnienia rozsianego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13710308T PL2812351T3 (pl) 2012-02-10 2013-02-08 Kompozycja farmaceutyczna do leczenia stwardnienia rozsianego

Country Status (9)

Country Link
US (2) US20150080313A1 (pl)
EP (1) EP2812351B1 (pl)
DK (1) DK2812351T3 (pl)
ES (1) ES2684725T3 (pl)
HU (1) HUE039044T2 (pl)
PL (2) PL398077A1 (pl)
PT (1) PT2812351T (pl)
SI (1) SI2812351T1 (pl)
WO (1) WO2013117742A2 (pl)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2712623A1 (en) * 2006-05-05 2014-04-02 Opexa Therapeutics T-cell vaccine
PT2737906T (pt) * 2008-01-25 2018-05-28 Vianex S A Vacinas terapeuticas

Also Published As

Publication number Publication date
US20190201484A1 (en) 2019-07-04
DK2812351T3 (en) 2018-07-09
PL2812351T3 (pl) 2018-09-28
HUE039044T2 (hu) 2018-12-28
WO2013117742A2 (en) 2013-08-15
US20150080313A1 (en) 2015-03-19
WO2013117742A3 (en) 2014-02-20
EP2812351A2 (en) 2014-12-17
ES2684725T3 (es) 2018-10-04
EP2812351B1 (en) 2018-03-28
SI2812351T1 (sl) 2018-11-30
PT2812351T (pt) 2018-08-01

Similar Documents

Publication Publication Date Title
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
PH12016500619A1 (en) Dry powder inhaler
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
BR112015027297A8 (pt) administração local e concomitante de nanocarreadores sintéticos tolerogênicos para reduzir hipersensibilidade dos tipos i e iv
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
MX340985B (es) Compuestos de n-heteroarilo.
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
EA201391689A1 (ru) Система доставки лекарственного средства
WO2010098627A3 (ko) 약제학적 제제
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
JP2014520892A5 (pl)
WO2015009731A3 (en) Azacyclic constrained analogs of fty720
WO2015001163A3 (es) Nanopartículas lipídicas para la cicatrización de heridas
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
BR112015027436A2 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
IN2014DN10134A (pl)
PL398077A1 (pl) Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
UA69674U (ru) Способ лечения больных на эритематозно-бульозной рожей